
‘Guardian' creatures — that carry their young on their backs — are new species
The animals are about 1.5 inches long, but the males' bare backs can hold tadpoles carefully positioned on the skin as they are moved between shallow puddles.
The guardian frogs of Borneo have long been broken up into two distinct species: Limnonectes palavanensis, the smooth guardian frog, and Limnonectes finchi, the rough guardian frog.
Now, as researchers studied these frogs across the Malaysian islands, they noticed that frogs previously thought to belong to the smooth species had different calls, according to a study published June 23 in the peer-reviewed journal Zootaxa.
The smooth guardian frogs aren't one species at all — they're seven different species.
Limnonectes palavanensis was first identified on the island of Palawan in the Phillipines in 1894 and was later found in Borneo in 1897, according to the study.
The animals were collected by British civil servant and naturalist Alfred Hart Everett, but it wasn't until the mid-20th century that researchers first observed 'tadpole-transport' by the species, researchers said.
After researchers noticed discrepancies in the calls of different smooth guardian frogs, they set out to test their theory that there may be more than one species present on Borneo by collecting frogs by hand at night and photographing them in the field, according to the study.
The original L. palavanensis is described as being small in size with a 'moderately sturdy' body that is widest toward the head and tapers back toward the groin.
Their skin is like that of untanned leather, researchers said, and small bumps are scattered on the upper eyelid and back.
The species is brown with blackish bands, and the sides of the body have white in them, according to the study.
Researchers gave the species a new common name: the Palawan guardian frog.
Genetic testing confirmed the presence of seven other closely related species that had been misidentified as the Palawan guardian frog, according to the study.
Limnonectes gunungensis, L. kinabaluensis, L. nephophilus, L. oreibates, L. phylax, L. sarawakensis and L. suboliferus were described by researchers.
L. gunungensis, or the mountain guardian frog, is found in the 'moist leaf litter' near small streams in the mountains of Sarawak, Malaysia, according to the study.
The Kinabalu guardian frog, or L. kinabaluensis, was 'collected under a log, another one on a rock, others on the ground and under leaves in leaf litter,' researchers said. The frog was also observed releasing tadpoles from its back into a puddle in Kinabalu National Park.
L. nephophilus earns its common name, the cloud-forest guardian frog, from its home in the montane cloud forests of Gunung Mulu and Gunung Murud, according to the study. A tadpole of the species was found in a small pool between rocks in a dried stream bed.
The Penrissen guardian frog, L. oreibates, makes slow chirping calls and derives its name from the ancient Greek word for 'mountaineer,' according to the study. Another male of this species was found along an intermittent stream with tadpoles on his back.
L. phylax kept the common name of the smooth guardian frog because males were found guarding their eggs before reaching the tadpole stage, researchers said. Once the eggs hatch, the tadpoles hitch a ride on their father to a close body of water.
The Sarawak guardian frog, L. sarawakensis, was found in Lambir Hills National Park and has a long rising trill of a call, according to the study. Tadpoles were discovered in 'pools of small intermittent streams, in low shallow buttress tank, in a water-filled hole in a log, in small isolated rain pools on forest floor and in a shallow puddle with silky bottom and scattered leaves,' researchers said.
The last new species, L. suboliferus, was found in a place called 'frog pond' in Kubah National Park, according to the study. The western guardian frog earns its name from the Latin words meaning 'the one that carries the offspring.'
The research team includes J. Maximilian Dehling, Dario N. Neokleous, Indraneil Das, T. Ulmar Grafe, Pui Yong Min and Stefan T. Hertwig.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Miami Herald
3 days ago
- Miami Herald
Rare and ‘secretive' snake — that can climb trees — found in Vietnam rainforest
In the protected, undisturbed limestone forests of central Vietnam, a 'secretive' creature emerged at nightfall. In a scene framed by the opening of a karst cave, the 20-inch black and cream-colored banded snake targeted an unknowing skink. It is an adept hunter, able to move swiftly over rocky terrain and even climb trees. Researchers have now confirmed the snake, discovered in Phong Nha-Ke Bang National Park in the Northern Annamites, is a new species called Lycodon calcarophilus, or the Limestone wolf snake, according to a study published Aug. 12 in the peer-reviewed journal Zootaxa. The mountainous rainforest region where the limestone wolf snake was found is considered to be one of Vietnam's 'most significant protected areas' in terms of reptile and amphibian diversity, according to the study. 'Numerous studies have emphasised the remarkable species richness' and the large number of species that exist only in the karstic region and nowhere else in the world, researchers said. The new species is described as being relatively small compared to related species. Its blackish-brown body is 'laterally compressed' with between 19 and 25 'pinkish-cream' colored bands, researchers said. The new species has a head that is angular, slightly flattened, and distinct from the rest of its body, according to the study. Researchers said the species is 'likely rare, as suggested by the very limited number of observations.' The team encountered just six during their fieldwork. However, the limestone wolf snake is likely to be found in 'limestone massifs outside the park boundaries, where forest habitats are increasingly threatened by anthropogenic activities.' The discovery of the new species brings the known number of Lycodon species in Vietnam to 17, according to researchers. Researchers recommend listing the new species as data deficient on the International Union for Conservation of Nature's Red List until more field surveys can determine its threatened status. The research team included Gernot Vogel, Andrey M. Bragin, Nikolay A. Poyarkov and Tan Van Nguyen.


Miami Herald
07-08-2025
- Miami Herald
‘Muscular' creature with ‘thick neck' found sleeping in tree. It's a new species
In a mountain forest of Vietnam, a 'muscular' creature with a 'thick neck' climbed onto a tree branch and fell asleep 'on a tangle of' plants above a trail. Its 'jade' green coloring helped it blend in with its surroundings, but it wasn't quite hidden enough. Passing scientists noticed the sleeping animal — and discovered a new species. A team of researchers visited dozens of sites throughout Vietnam and Laos between 2013 and 2024 as part of an ongoing effort to survey wildlife, according to a study published Aug. 6 in the peer-reviewed journal Zootaxa. Over the course of the surveys, researchers found several 'elusive' snakes, the study said. The snakes looked a bit like a known and widespread species, but upon closer analysis, researchers realized they'd discovered a new species: Gonyosoma iadinum, or jade tree snake. Jade tree snakes are considered 'medium-sized,' reaching up to 3 feet, 5 inches long, the study said. They have 'slender,' 'firm and muscular' bodies, 'relatively thick neck(s)' and 'long' tails capable of grasping. Their heads are 'much elongated' with 'rather thick' snouts and 'large' eyes 'varying from yellowish-green to bluish-green.' n Photos show the coloring of the new species, which can be 'bright green, grass green, or bluish green.' Researchers said they named the new species after the ancient Greek word for 'jade' because of its eyes and 'body colouration resembling polished jade jewels.' In between their scales, jade tree snakes have 'black and white' skin, which looks almost like netting 'when the snake inflates the anterior (front) part of its body,' the study said. Jade tree snakes live in mountain forests between elevations of about 2,150 to 5,800 feet, researchers said. They are tree-dwellers with an 'elusive nature,' 'primarily' active during the day and often found in 'closed-canopy evergreen forests.' One jade tree snake was found 'sleeping on a tangle of Gramineae grasses and Brainea insignis ferns overhanging a path along a river terrace,' researchers said. Other snakes were found near the summit of a mountain ridge, on a tree 'over a slow-flowing stream' and 'actively moving across a road.' So far, jade tree snakes have been found at 11 sites in 'central and southern Vietnam and central and southern Laos,' neighboring countries in Southeast Asia, the study said. The new species is threatened by 'habitat loss and degradation,' 'road mortality' and 'occasionally (being) misidentified and killed due to its superficial resemblance to green pit vipers,' but researchers still considered it a species of 'least concern.' The new species was identified by its scale pattern, body coloring, eye coloring, head shape and proportions and other subtle physical features, the study said. DNA analysis found the new species had at least 8% genetic divergence from other tree snakes. The research team included Nikolay Poyarkov, Andrey Bragin, Sabira Idiiatullina, Tuan Anh Tran, Dac Xuan Le, Patrick David and Tan Van Nguyen.


Business Upturn
06-08-2025
- Business Upturn
Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment
Presented data highlights the potential of Annamycin for treating broad range of human cancers, including high-need oncology indications Annamycin currently in late-stage clinical development in combination with cytarabine for the treatment of AML; Anticipated preliminary data readout in 2H 2025 HOUSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) ('Moleculin' or the 'Company'), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the presentation of encouraging preclinical data for its lead drug candidate, Annamycin, also known by its non-proprietary name of naxtarubicin, which demonstrated significant efficacy against various primary and metastatic liver cancers, including hepatocellular carcinoma (HCC), colorectal liver metastases, and pancreatic ductal adenocarcinoma (PDAC) liver metastases. This is believed to be the result of targeted accumulation in the liver and other organs. These findings were highlighted in a poster titled ' Liposomal Annamycin (L-ANN) Efficacy Against Primary and Metastatic Liver Cancers , ' presented by Dr. Waldemar Priebe, Lead Author and Chairman of the Scientific Advisory Board at Moleculin at the recently held Shelby-Lavine Pancreatic Cancer Symposium at MD Anderson Cancer Center. Key Highlights Targeted Accumulation in Organs: The preclinical studies confirmed that Annamycin exhibits distinct organotropic properties, leading to significantly higher concentrations in the liver, spleen, lungs, and pancreas when compared to doxorubicin (DOX). This targeted accumulation is critical for effectively treating liver-localized tumors. The preclinical studies confirmed that Annamycin exhibits distinct organotropic properties, leading to significantly higher concentrations in the liver, spleen, lungs, and pancreas when compared to doxorubicin (DOX). This targeted accumulation is critical for effectively treating liver-localized tumors. Efficacy in Orthotopic Hepatocellular Carcinoma (HCC) Models: Annamycin demonstrated excellent anti-tumor activity in orthotopic HCC models (Hepa 1-6 Luc), showing a marked reduction in tumor progression and improved survival rates in treated animals compared to vehicle controls. Annamycin demonstrated excellent anti-tumor activity in orthotopic HCC models (Hepa 1-6 Luc), showing a marked reduction in tumor progression and improved survival rates in treated animals compared to vehicle controls. Potent Impact on Colorectal Liver Metastasis: In an experimental liver metastatic model of colorectal carcinoma (CT26 Luc), Annamycin significantly inhibited metastatic growth and extended survival, highlighting its potential for addressing liver metastases in colon cancer that affects close to 50% of patients. In an experimental liver metastatic model of colorectal carcinoma (CT26 Luc), Annamycin significantly inhibited metastatic growth and extended survival, highlighting its potential for addressing liver metastases in colon cancer that affects close to 50% of patients. Promising Results in Pancreatic Cancer Liver Metastasis: Annamycin also showed compelling efficacy in liver-implanted human pancreatic ductal adenocarcinoma (MIA PaCa-2), leading to inhibition of tumor growth, suggesting its potential role in managing advanced pancreatic cancer with liver involvement. Annamycin also showed compelling efficacy in liver-implanted human pancreatic ductal adenocarcinoma (MIA PaCa-2), leading to inhibition of tumor growth, suggesting its potential role in managing advanced pancreatic cancer with liver involvement. Favorable Safety Profile: Consistent with previous preclinical and clinical findings, Annamycin continued to show low or no cardiotoxicity, a significant advantage over traditional anthracyclines like doxorubicin, which are often limited by dose-dependent cardiac side effects. This safety profile was previously observed in clinical trials, where 32 out of 42 subjects reviewed received more than the FDA-established lifetime maximum allowable level of anthracycline without evidence of cardiotoxicity. 'We are incredibly encouraged by these preclinical results, which further validate Annamycin's potential as a powerful and differentiated therapeutic agent for liver cancers,' said Dr. Priebe. 'The ability of Annamycin to concentrate effectively in the liver, combined with its demonstrated efficacy across multiple aggressive liver cancer models and its favorable cardiotoxicity profile, positions it as a highly promising candidate for patients facing these devastating diseases. We believe these data provide a strong foundation for advancing Annamycin in clinical development for these indications, offering new hope where treatment options are often limited.' Walter Klemp, Chairman and CEO of Moleculin, added, 'We continue to be strongly encouraged by the potential of Annamycin. Beyond our preliminary programs in AML and soft tissue sarcoma lung metastases (STS lung mets), we continue to advance and develop Annamycin through multiple investigator-initiated studies to further unlock its potential as a treatment option for many other types of cancers. We believe this preclinical data highlights that potential and provides additional validation of its unique pharmacological profile and importantly showcases the opportunity for its use across a wide range of cancers.' Moleculin's novel drug candidate is being positioned to become the first ever non-cardiotoxic anthracycline to be approved and is currently being developed for the treatment of AML and STS lung mets. For more information, please visit About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents. Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications. For more information about the Company, please visit and connect on X, LinkedIn and Facebook. Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the whether the preclinical results described above are able to be reproduced in clinical trials. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company's ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including 'believes,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'may,' 'could,' 'might,' 'will,' 'should,' 'approximately' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. 'Risk Factors' in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775 [email protected]